Kimberly-Clark is redrawing the map

New deal, new org chart

Kimberly-Clark is basically handing itself a corporate makeover before the ink is even dry on its Kenvue deal. Once the acquisition closes in the second half of 2026, the combined business will be organized into four separate segments, with North America as the heavyweight at roughly $18 billion in annual sales.

Why the breakup matters

This is what happens when two household-name brand warehouses get stuffed into the same trench coat. The new structure also carves out EMEA at about $5 billion, plus two Asia Pacific businesses that each ring up around $4.3 billion. In other words: fewer “one big blob” vibes, more regional accountability.

The brand pile gets even bigger

The combo would put Kenvue names like Listerine, Band-Aid, and Tylenol next to Kimberly-Clark staples like Kleenex, Scott, and Huggies. That gives the new company 10 billion-dollar brands and more than $31.6 billion in annual sales — a lot of shelf space, and a lot of integration risk.

Big picture

For investors, the key question isn’t whether these brands are famous. They absolutely are. It’s whether Kimberly-Clark can stitch them together without turning a tidy consumer staples story into a marathon of regulatory paperwork, execution headaches, and “synergy” PowerPoints. The deal still needs regulatory clearance, and the clock is now officially ticking.